Strengths and limitations of microarray-based phenotype prediction: Lessons learned from the IMPROVER Diagnostic Signature Challenge

Bioinformatics

Volumn 29, Issue 22, 2013, Pages 2892-2899

  Tarca, Adi L ^a,b   Lauria, Mario ^c   Unger, Michael ^d   Bilal, Erhan ^e   Boue, Stephanie ^f   Dey, Kushal Kumar ^d   Hoeng, Julia ^f   Koeppl, Heinz ^d   Martin, Florian ^f   Meyer, Pablo ^e   Nandy, Preetam ^d   Norel, Raquel ^e   Peitsch, Manuel ^f   Rice, Jeremy J ^e   Romero, Roberto ^b   Stolovitzky, Gustavo ^e   Talikka, Marja ^f   Xiang, Yang ^f   Zechner, Christoph ^d  

^a Wayne State University   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF TRENTO   (Italy)

^d ETH ZURICH   (Switzerland)

^e IBM T J WATSON RESEARCH CENTER   (United States)

^f PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG NEOPLASMS; MOLECULAR DIAGNOSIS; MULTIPLE SCLEROSIS; PHENOTYPE; PROCEDURES; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; LUNG TUMOR; METHODOLOGY;

DISEASE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84885895107     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btt492     Document Type: Article

References (30)

1. (2006) NSABP study confirms oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology (Williston Park), 20, 789-790.
2. Acharya, C.R. et al. (2012) Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008; 299:1574-1587.
3. Acharya CR, et al. (2012) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA, 307, 453.
4. Baldi, P. et al. (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics, 16, 412-424.
5. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. B, 57, 289-300.
6. Bittner, M. et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406, 536-540.
7. Gordon, G.J. et al. (2002) Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res., 62, 4963-4967.
8. Hresko, A. and Haga, S.B. (2012) Insurance Coverage Policies for Personalized Medicine. J. Pers. Med., 2, 201-216.
9. Irizarry, R.A. et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-264.
10. Kaklamani, V. (2006) A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert. Rev. Mol. Diagn., 6, 803-809.
11. Langley, R.G. and Ellis, C.N. (2004) Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J. Am. Acad. Dermatol., 51, 563-569.
12. Lauria, M. (2013) Rank-based transcriptional signatures: a novel approach to diagnostic biomarker definition and analysis. Syst. Biomed., in press.
13. Luo, J. et al. (2010) A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J., 10, 278-291.
14. Marbach, D. et al. (2012)Wisdom of crowds for robust gene network inference. Nat. Methods, 9, 796-804.
15. Matthews, B.W. (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim. Biophys. Acta, 405, 442-451.
16. Meyer, P. et al. (2011) Verification of systems biology research in the age of collaborative competition. Nat. Biotechnol., 29, 811-815.
17. Meyer, P. et al. (2012) Industrial methodology for process verification in research (IMPROVER): toward systems biology verification. Bioinformatics, 28, 1193-1201.
18. Mook, S. et al. (2007) Individualization of therapy using MammaPrint: from development to the MINDACT Trial. Cancer Genomics Proteomics, 4, 147-155.
19. Nandy, P. et al. (2013) Learning diagnostic signatures from microarray data using L1-regularized logistic regression. Syst. Biomed., in press.
20. Nguyen, B. et al. (2012) Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann. Surg. Oncol., 19, 3257-3263.
21. Perou, C.M. et al. (2000)Molecular portraits of human breast tumours. Nature, 406, 747-752.
22. Prill, R.J. et al. (2010) Towards a rigorous assessment of systems biology models: the DREAM3 challenges. PLoS One, 5, e9202.
23. Schena, M. et al. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270, 467-470.
24. Shannon, P. et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 13, 2498-2504.
25. Shi, L. et al. (2010) The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol., 28, 827-838.
26. Tarca, A.L. et al. (2007) Machine learning and its applications to biology. PLoS. Comput. Biol., 3, e116.
27. Tarca, A.L., Than, N.G. and Romero, R. (2013) Methodological Approach from the Best Overall Team in the IMPROVER Diagnostic Signature Challenge. Syst. Biomed., in press.
28. Tibshirani, R. et al. (1996) Regression shrinkage and selection via the lasso. J. Royal. Statist. Soc B., 58, 267-288.
29. Yamani, M.H. et al. (2007a) Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. Clin. Transplant., 21, 523-525.
30. Yamani, M.H. et al. (2007b) Transplant vasculopathy is associated with increased AlloMap gene expression score. J. Heart Lung Transplant., 26, 403-406.